CareDx, Inc (NASDAQ:CDNA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $28.33.
A number of brokerages have commented on CDNA. HC Wainwright restated a “neutral” rating and set a $26.00 price target on shares of CareDx in a research note on Tuesday, January 14th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. The Goldman Sachs Group lifted their price target on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. BTIG Research dropped their target price on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. Finally, Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and decreased their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th.
Check Out Our Latest Stock Report on CDNA
Insider Activity at CareDx
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP bought a new stake in shares of CareDx in the 3rd quarter worth approximately $27,000. Thompson Davis & CO. Inc. raised its stake in shares of CareDx by 6.3% in the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock valued at $344,000 after buying an additional 950 shares during the period. Royce & Associates LP lifted its position in shares of CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock valued at $12,280,000 after buying an additional 1,000 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company’s stock worth $406,000 after acquiring an additional 1,151 shares during the period. Finally, Rhumbline Advisers increased its holdings in CareDx by 1.8% in the 4th quarter. Rhumbline Advisers now owns 81,201 shares of the company’s stock worth $1,738,000 after acquiring an additional 1,451 shares during the last quarter.
CareDx Price Performance
Shares of CDNA opened at $23.10 on Friday. The stock has a 50-day moving average of $22.91 and a 200-day moving average of $25.14. CareDx has a one year low of $7.42 and a one year high of $34.84. The company has a market cap of $1.24 billion, a PE ratio of -8.56 and a beta of 1.87.
CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. During the same quarter in the previous year, the company posted ($0.43) earnings per share. The company’s quarterly revenue was up 23.4% on a year-over-year basis. Analysts expect that CareDx will post -0.9 EPS for the current fiscal year.
About CareDx
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
- Five stocks we like better than CareDx
- How to Start Investing in Real Estate
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Upcoming IPO Stock Lockup Period, Explained
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.